Thompson Quoted On Planned FDA, Industry Meeting

FDA Week

Bradley Thompson, a Member of the Firm in the Health Care and Life Sciences Practice in the Washington, DC office, was quoted on the FDA's decision to meet with industry officials, in order to discuss a proposed rule on combination-product good manufacturing practices.
The article, "Proposed Combo Products Rule to Trigger FDA, Industry Meeting," stated that the FDA plans to hold an in-depth session with industry to discuss how the rule will apply to complicated, real-life situations.   

It could take years for FDA to issue a final version of the rule, and industry wants guidance on how to proceed in the interim, and the upcoming meeting could provide such guidance, Thompson said.